Description of CRISPR/Cas9 development and its prospect in hepatocellular carcinoma treatment

Hepatocellular carcinoma (HCC) is one of the most common malignancies today. Patients suffer from HCC since its high malignancy and limited treatment means. With the development of genetic research, new therapeutic strategy comes up in the way of gene editing. Clustered regularly interspaced short p...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Xiaoling, Ma, Weijie, Mei, Chengjie, Chen, Xi, Yao, Ye, Liu, Yingyi, Qin, Xian, Yuan, Yufeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7268395/
https://www.ncbi.nlm.nih.gov/pubmed/32487115
http://dx.doi.org/10.1186/s13046-020-01603-0
_version_ 1783541608842526720
author Wu, Xiaoling
Ma, Weijie
Mei, Chengjie
Chen, Xi
Yao, Ye
Liu, Yingyi
Qin, Xian
Yuan, Yufeng
author_facet Wu, Xiaoling
Ma, Weijie
Mei, Chengjie
Chen, Xi
Yao, Ye
Liu, Yingyi
Qin, Xian
Yuan, Yufeng
author_sort Wu, Xiaoling
collection PubMed
description Hepatocellular carcinoma (HCC) is one of the most common malignancies today. Patients suffer from HCC since its high malignancy and limited treatment means. With the development of genetic research, new therapeutic strategy comes up in the way of gene editing. Clustered regularly interspaced short palindromic repeat/CRISPR-associated nuclease 9 (CRISPR/Cas9) was discovered as an immune sequence in bacteria and archaea. After artificial transformation and follow-up research, it is widely used as a gene editing tool. In this review, the development of CRISPR/Cas9 is summarized in retrospect. Through the evaluation of novel research in HCC, it is concluded that CRISPR/Cas9 would promote cancer research and provide a new tool for genetic treatment in prospect.
format Online
Article
Text
id pubmed-7268395
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-72683952020-06-07 Description of CRISPR/Cas9 development and its prospect in hepatocellular carcinoma treatment Wu, Xiaoling Ma, Weijie Mei, Chengjie Chen, Xi Yao, Ye Liu, Yingyi Qin, Xian Yuan, Yufeng J Exp Clin Cancer Res Review Hepatocellular carcinoma (HCC) is one of the most common malignancies today. Patients suffer from HCC since its high malignancy and limited treatment means. With the development of genetic research, new therapeutic strategy comes up in the way of gene editing. Clustered regularly interspaced short palindromic repeat/CRISPR-associated nuclease 9 (CRISPR/Cas9) was discovered as an immune sequence in bacteria and archaea. After artificial transformation and follow-up research, it is widely used as a gene editing tool. In this review, the development of CRISPR/Cas9 is summarized in retrospect. Through the evaluation of novel research in HCC, it is concluded that CRISPR/Cas9 would promote cancer research and provide a new tool for genetic treatment in prospect. BioMed Central 2020-06-01 /pmc/articles/PMC7268395/ /pubmed/32487115 http://dx.doi.org/10.1186/s13046-020-01603-0 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Wu, Xiaoling
Ma, Weijie
Mei, Chengjie
Chen, Xi
Yao, Ye
Liu, Yingyi
Qin, Xian
Yuan, Yufeng
Description of CRISPR/Cas9 development and its prospect in hepatocellular carcinoma treatment
title Description of CRISPR/Cas9 development and its prospect in hepatocellular carcinoma treatment
title_full Description of CRISPR/Cas9 development and its prospect in hepatocellular carcinoma treatment
title_fullStr Description of CRISPR/Cas9 development and its prospect in hepatocellular carcinoma treatment
title_full_unstemmed Description of CRISPR/Cas9 development and its prospect in hepatocellular carcinoma treatment
title_short Description of CRISPR/Cas9 development and its prospect in hepatocellular carcinoma treatment
title_sort description of crispr/cas9 development and its prospect in hepatocellular carcinoma treatment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7268395/
https://www.ncbi.nlm.nih.gov/pubmed/32487115
http://dx.doi.org/10.1186/s13046-020-01603-0
work_keys_str_mv AT wuxiaoling descriptionofcrisprcas9developmentanditsprospectinhepatocellularcarcinomatreatment
AT maweijie descriptionofcrisprcas9developmentanditsprospectinhepatocellularcarcinomatreatment
AT meichengjie descriptionofcrisprcas9developmentanditsprospectinhepatocellularcarcinomatreatment
AT chenxi descriptionofcrisprcas9developmentanditsprospectinhepatocellularcarcinomatreatment
AT yaoye descriptionofcrisprcas9developmentanditsprospectinhepatocellularcarcinomatreatment
AT liuyingyi descriptionofcrisprcas9developmentanditsprospectinhepatocellularcarcinomatreatment
AT qinxian descriptionofcrisprcas9developmentanditsprospectinhepatocellularcarcinomatreatment
AT yuanyufeng descriptionofcrisprcas9developmentanditsprospectinhepatocellularcarcinomatreatment

Ejemplares similares